<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>疫苗对Covid变体有效 Vaccines Are Effective Against Covid Variants</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Vaccines Are Effective Against Covid Variants<br/>疫苗对Covid变体有效 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-03-22 00:00:11</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/3/b1acc7d8c465a295cc75dc85be07acd2.png"><img src="http://img2.diglog.com/img/2021/3/b1acc7d8c465a295cc75dc85be07acd2.png" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Cite  This   Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.  JAMA. Published online March 19, 2021. doi:10.1001/jama.2021.4388</p><p>引用这个edara vv，hudson wh，xie x，ahmed r，suthar ms。在感染和疫苗接种后，中和针对SARS-COV-2变体的抗体。贾马。 2021年3月19日在线发布.Doi：10.1001 / Jama.2021.4388</p><p>        Serum neutralizing antibodies rapidly appear after SARS-CoV-2 infection  1 and vaccination  2 and are maintained for several months.  3 , 4 The emergence of SARS-CoV-2 variants has raised concerns about the breadth of neutralizing-antibody responses. We compared the neutralizing-antibody response to 4 variants in infected and vaccinated individuals to determine how mutations within the spike protein are associated with virus neutralization.</p><p>        在SARS-COV-2感染1和疫苗接种2后，血清中和抗体迅速出现，并保持几个月。 3,4 SARS-COV-2变体的出现提出了关于中和抗体应答的宽度的担忧。将中和抗体对感染和接种疫苗的个体中的4个变体进行比较，以确定尖刺蛋白质内的突变是如何与病毒中和相关的。</p><p>          Serum samples were obtained from 3 groups of individuals. At Emory University, hospitalized adults with SARS-CoV-2 infection (polymerase chain reaction confirmed) were enrolled 5 to 19 days after symptom onset (July 2020). Infected convalescent individuals (polymerase chain reaction or antigen test confirmed) were enrolled 32 to 94 days after symptom onset (March to August 2020). Deidentified serum samples drawn 14 days after the second dose (100-μg cohort) from individuals in the mRNA-1273 phase 1 clinical trial  2 were obtained from the National Institutes of Health. See the eAppendix in the  Supplement for participant details. Institutional review board approval was obtained from Emory University and Advarra; all participants provided written informed consent.</p><p>          从3组个体中获得血清样品。在埃默里大学，住院成人具有SARS-COV-2感染（确认的聚合酶链反应）在症状发作后征收5至19天（7月2020年）。感染的临时性个体（聚合酶链反应或证实证实的抗原试验）在症状发作后（3月至2020年3月）征收32至94天。从国家卫生研究院获得来自MRNA-1273阶段1临床试验2中的闭合性的第二剂量（100μg队长）后14天绘制的血清样品。请参阅“参与者详细信息补充”中的EAPPendix。机构审查委员会批准是从埃默里大学和Advarra获得的批准;所有参与者都提供了书面知情同意书。</p><p>    Four variants were examined, chosen to represent the original SARS-CoV-2 strain and emerging variants with mutations in the spike protein. The first variant, nCoV/USA_WA1/2020 (A.1 lineage), closely resembled the original Wuhan strain and the spike used in the mRNA-1273 vaccine, and was propagated from an infectious SARS-CoV-2 clone. The second variant, EHC-083E (B.1 lineage), containing a D614G mutation within the spike, was the predominant circulating strain at the time of the study and was isolated from a residual nasopharyngeal swab from a patient in Atlanta, Georgia, in March 2020 (SARS-CoV-2/human/USA/GA-EHC-083E/2020). The third variant, B.1.1.7 (SARS-CoV-2/human/USA/CA_CDC_5574/2020), was originally identified in the UK and of concern because of increased transmissibility. It contained several spike mutations and was isolated from a residual nasopharyngeal swab from a patient in San Diego, California, in December 2020. The fourth variant, N501Y SARS-CoV-2 virus, containing a mutation in the critical receptor binding domain of the spike that is present across multiple emerging variants, including the B.1.1.7 variant in this study, was generated from an infectious clone as previously described.  5 This virus is not found in nature.</p><p>    检查四种变体，选择原始的SARS-COV-2菌株和具有尖峰蛋白质中的突变的新出现变体。第一变型NCOV / USA_WA1 / 2020（A.1谱系），与MRNA-1273疫苗中使用的原始武汉菌株和尖峰相似，并从传染性SARS-COV-2克隆繁殖。第二变型EHC-083E（B.1谱系）含有D614G突变在峰值内，在研究时是主要的循环菌株，并从亚特兰大，格鲁吉亚的患者中与患者的残留鼻咽拭子分离2020年3月（SARS-COV-2 /人类/美国/ GA-EHC-083E / 2020）。第三种变体B.1.1.7（SARS-COV-2 / HUMA / USA / CA_CDC_5574 / 2020）最初在英国识别，并且由于传播性增加而受到关注。它含有几种尖峰突变，并于2020年12月，从加利福尼亚州圣地亚哥的患者与患者的残留鼻咽拭子分离出来。第四种变体N501Y SARS-COV-2病毒，含有尖峰的临界受体结合结构域中的突变在多个新出现的变体上存在，包括本研究中的B.1.1.7变体，从如前所述的传染性克隆产生。 5本病毒本质上没有。</p><p>    Live-virus focus reduction neutralization tests (FRNTs) were performed as previously described.  6 See the eAppendix in the  Supplement for details on the laboratory methods. FRNT 50 titers, which represent the reciprocal dilution of serum that neutralizes 50% of the input virus, were interpolated with a 4-parameter nonlinear regression, and geometric mean titers (GMTs) were calculated with 95% CI in GraphPad Prism version 8.4.3. Kruskal-Wallis test was used to compare FRNT 50 GMTs between the variants, followed by Dunn’s multiple comparison post hoc test. We determined  P &lt; .05 (2 sided) to define statistical significance.</p><p>    如前所述进行实时病毒聚焦还原中和试验（FRNT）。 6有关实验室方法的详细信息，请参阅补充剂中的EAPPendix。 FRNT 50滴度，其代表血清的往复稀释，其中和50％的输入病毒，用4参数非线性回归插值，并用RappPad Prism版本8.4.3中的95％CI计算几何平均滴度（GMT） 。 Kruskal-Wallis测试用于比较VNT 50 GMTS在变体之间，其次是DUNN的多重比较后HOC测试。我们确定了p＆lt; .05（2面）定义统计显着性。</p><p>        Twenty acutely infected COVID-19 patients provided serum samples (mean age, 56.6 years; 50% men). The FRNT 50 GMT for the A.1 variant was 186 (95% CI, 90-383); for B.1, 110 (95% CI, 57-209); for B.1.1.7, 116 (95% CI, 62-215); and for N501Y, 141 (95% CI, 74-269). Comparison of the FRNT 50 GMT of the variants was not statistically significant ( Figure).</p><p>        二十令人敏锐的Covid-19患者提供血清样品（平均年龄，56.6岁; 50％）。 A.1变体的FRNT 50 GMT为186（95％CI，90-383）;对于B.1,110（95％CI，57-209）;对于B.1.1.7,116（95％CI，62-215）;对于N501Y，141（95％CI，74-269）。 FRNT 50的比较GMT的变体没有统计学意义（图）。</p><p>    Twenty convalescent individuals provided serum samples (mean age, 45 years; 55% men). The FRNT 50 GMT for the A.1 variant was 168 (95% CI, 113-249); for B.1, 91 (95% CI, 60-138); for B.1.1.7, 145 (95% CI, 96-220); and for N501Y, 145 (95% CI, 76-172). Comparison of the FRNT 50 GMT of the variants was not statistically significant.</p><p>    二十个康复人员提供了血清样本（平均年龄，45岁; 55％）。 A.1变体的FRNT 50 GMT为168（95％CI，113-249）;对于B.1,91（95％CI，60-138）;对于B.1.1.7,145（95％CI，96-220）;对于N501Y，145（95％CI，76-172）。 FRNT 50的GMT的比较没有统计学意义。 </p><p>    Serum samples were available for 14 mRNA-1273 vaccinated individuals  2 (age range, 18-55 years; 43% men). The FRNT 50 GMT for the A.1 variant was 1709 (95% CI, 1412-2069); for B.1, 804 (95% CI, 632-1023); for B.1.1.7, 965 (95% CI, 695-1341); and for N501Y, 994 (95% CI, 777-1272). Comparisons of the FRNT 50 GMT of B.1, B.1.1.7, and the N501Y variant were not statistically significant. The FRNT 50 GMTs for the B.1 ( P &lt; .001), B.1.1.7 ( P = .02), and N501Y ( P = .02) variants were statistically significantly lower than that for the A.1 variant.</p><p>血清样品可用于14 mRNA-1273接种疫苗的个体2（年龄范围，18-55岁; 43％）。 A.1变异的GMT 50MGT为1709（95％CI，1412-2069）;对于B.1,804（95％CI，632-1023）;对于B.1.1.7,965（95％CI，695-1341）;对于N501Y，994（95％CI，777-1272）。 B.1，B.1.1.7和N501Y变体的FRNT 50 GMT的比较没有统计学意义。 B.1（P＆lt;），B.1.1.7（P = .02）和N501Y（P = .02）变体的FRNT 50MGTS（p = .7）和N501Y（P = .02）变体比A.1变体的统计学显着低。</p><p>        This study found neutralizing activity of infection- and vaccine-elicited antibodies against 4 SARS-CoV-2 variants, including B.1, B.1.1.7, and N501Y. Because neutralization studies measure the ability of antibodies to block virus infection, these results suggest that infection- and vaccine-induced immunity may be retained against the B.1.1.7 variant. As additional variants emerge, neutralizing-antibody responses after infection and vaccination should be monitored.</p><p>        该研究发现，针对4个SARS-COV-2变体的感染和疫苗引发抗体的中和活性，包括B.1，B.1.1.7和N501Y。因为中和研究测量抗体阻断病毒感染的能力，所以这些结果表明感染和疫苗诱导的免疫可以保留在B.1.1.7变体上。作为额外的变体出现，应监测感染后的中和抗体反应和接种疫苗。</p><p>    Limitations include the small sample size, possible selection bias, lack of clinical outcomes, and how neutralization titers correlate with protection.</p><p>    限制包括小的样本大小，可能的选择偏差，缺乏临床结果，以及如何与保护相关。</p><p>                        Funding/Support: This work was supported in part by grants NIH P51 OD011132, 3U19AI057266-17S1 CCHI Immune Memory Supplement, U19AI090023, R01AI127799, R01AI148378, K99AI153736, and UM1AI148684 to Emory University; R00AG049092 and R24AI120942 to the University of Texas Medical Branch from the National Institute of Allergy and Infectious Diseases, National Institutes of Health; the Oliver S. and Jennie R. Donaldson Charitable Trust; the Emory Executive Vice President for Health Affairs Synergy Fund award; the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children’s Healthcare of Atlanta; COVID-Catalyst-I 3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine; Woodruff Health Sciences Center 2020 COVID-19 CURE Award; and the Vital Projects/Proteus funds.</p><p>                        资金/支持：这项工作部分由GRANT NIH P51 OD011132，3U19AI057266-17S1 CCHI免疫记忆补充，U19AI090023，R01AI12779，K99AI148378，K99AI148376和UM1AI148684到Emory大学; R00AG049092和R24AI120942到德克萨斯大学医学院，来自国家过敏和传染病，国家卫生研究院;奥利弗S.和Jennie R. Donaldson慈善信任;埃默里卫生协同基金奖副总裁;儿科研究联盟儿童感染和疫苗和亚特兰大的医疗保健中心; Covid-Catalyst-i 3来自伍德鲁夫健康科学中心和埃米洛医学院的资金;伍德拉夫健康科学中心2020 Covid-19治疗奖;和重要的项目/蛋白质资金。</p><p> Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p> 资助者/赞助商的作用：资助者在研究的设计和行为中没有作用;数据收集，管理，分析和解释;稿件的准备，审查或批准;并决定提交稿件出版物。</p><p> Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.</p><p> 免责声明：本报告中的调查结果和结论是作者的调查结果，并不一定代表疾病控制和预防中心的官方地位。</p><p> Additional Contributions: We acknowledge the following individuals for providing reagents, discussion, and editing of the manuscript: Emory University School of Medicine, Atlanta, Georgia: Katharine Floyd, BS, Lilin Lai, MD, Meredith Gardner, PhD, Anne Piantadosi, MD, Jesse J. Waggoner, MD, Ahmed Babiker, MBBS, David S. Stephens, MD, Evan J. Anderson, MD, Srilatha Edupuganti, MD, MPH, Nadine Rouphael, MD, MSc, Grace Mantus, MS, Lindsay Nyhoff, PhD, Jens Wrammert, PhD, Max W. Adelman, MD, MSc, Rebecca Fineman, BS, Shivan Patel, MD, Rebecca Byram, ME, Dumingu Nipuni Gomes, MPH, Garett Michael, BS, BA, Hayatu Abdullahi, MD, Erin M. Scherer, PhD, Nour Beydoun, MD, Bernadine Panganiban, BS, Nina McNair, BS, Kieffer Hellmeister, BA, Jamila Pitts, BS, Joy Winters, MS, Jennifer Kleinhenz, BS, Jacob Usher, BS, and James O’Keefe, MD; UC San Diego School of Medicine, California: Louise C. Laurent, MD, PhD, Peter De Hoff, PhD, Holly Valentine, BA, MPH, Rob Knight, PhD, Phoebe Seaver, BA, MPH, Gene W. Yeo, PhD, MBA, Shashank Sathe, BTech, MS, and Aaron Carlin, MD, PhD; The Scripps Research Institute, La Jolla, California: Kristian G. Andersen, PhD, Mark Zeller, PhD, Karthik Gangavarapu, BS, Catie Anderson, BA, and Alaa Abdel Latif, BA, MPhil, BS; University of Texas Medical Branch, Galveston: Kumari Lokugamage, PhD, Vineet Menachery, PhD, Pei-Yong Shi, PhD; and Centers for Disease Control and Prevention, Atlanta, Georgia: Natalie Thornburg, PhD, Azaibi Tamin, PhD, Jennifer L. Harcourt, PhD, Maureen Diaz, PhD, Suxiang Tong, PhD, Ying Tao, PhD, Jing Zhang, PhD, Phili Wong, MS, Shilpli Jain, PhD, and Jennifer Folster, PhD. No one received financial compensation for his or her contributions. We thank the mRNA-1273 phase 1 study team and the Division of Microbiology and Infectious Diseases for providing clinical samples.</p><p> 额外的贡献：我们承认下列个人提供试剂，讨论和编辑稿件：埃默里大学医学院，佐治亚州亚特兰大：Katharine Floyd，BS，Lilin Lai，MD，Meredith Gardner，Phd，Anne Piantadosi，MD， Jesse J. Wagoner，MD，Ahmed Babiker，MBBS，David S. Stephens，MD，Evan J. Anderson，MD，SRilara Edupuganti，MD，MPH，Nadine Rouphael，MD，MSC，Grace Mantus，MS，Lindsay Nyhoff，Phd， Jens Wrammert，Phd，Max W. Adelman，MD，MSC，Rebecca Fineman，BS，Shivan Patel，MD，Rebecca Byram，Me，Dumingu Nipuni Gomes，MPH，Garett Michael，BS，BA，Hayatu Abdullahi，MD，Erin M. Scherer，Phd，Nour Beydoun，MD，Bernadine Panganiban，BS，Nina McNair，BS，Kieffer Hellmeister，BA，Jamila Pitts，BS，Joy Winters，MS，Jennifer Kleinhenz，BS，Jacob Esher，BS和James O'Keefe， MD;加利福尼亚州大学圣地亚哥医学院：Louise C. Laurent，MD，博士，彼得德霍夫，博士，霍莉情人节，BA，MPH，Rob Knight，Phd，Phoebe Seaver，Ba，MPH，基因W. Yeo，Phd， MBA，Shashank Sathe，Btech，MS和Aaron Carlin，MD，PHD; Scripts Research Institute，加利福尼亚拉霍纳：克里斯蒂安G.安德森，博士，马克拉勒，博士，Karthik Gangavarapu，BS，Catie Anderson，Ba和Alaa Abdel Latif，Ba，Mphil，BS;德克萨斯大学医学院，加尔维斯顿：Kumari Lokugamage，Phd，vineet Menachery，Phd，Pei-Yong Shi，PHD;和疾病控制和预防中心，佐治亚州亚特兰大：娜塔莉·托尔堡，博士，阿扎比·塔彭，博士，詹妮弗L. Harcourt，博士，Maureen Diaz，博士，苏翔塘，博士，英文，博士，景张，博士，博士Wong，MS，Shilpli Jain，Phd和Jennifer Folster，博士学位。没有人为他或她的贡献收到财务赔偿。我们感谢MRNA-1273阶段1研究团队和微生物学和传染病的分裂，用于提供临床样本。 </p><p>      1. Suthar  MS﻿, Zimmerman  MG﻿, Kauffman  RC﻿,   et al.  Rapid generation of neutralizing antibody responses in COVID-19 patients. ﻿   Cell Rep Med. 2020;1(3):100040. doi: 10.1016/j.xcrm.2020.100040 PubMed Google Scholar</p><p>1.制度 女士，Zimmerman MG，Kauffman. rc， 等等。 Covid-19患者中的中和抗体反应的快速产生。细胞Rep Med。 2020; 1（3）：100040。 DOI：10.1016 / J.XCRM.2020101040 PubMed Google学者</p><p> 2. Jackson  LA﻿, Anderson  EJ﻿, Rouphael  NG﻿,   et al; mRNA-1273 Study Group.  An mRNA vaccine against SARS-CoV-2. ﻿   N Engl J Med. 2020;383(20):1920-1931. doi: 10.1056/NEJMoa2022483 PubMed Google Scholar Crossref</p><p> 杰克逊 拉，安德森 EJ，Rouphael. ng， 等等; mRNA-1273研究组。针对SARS-COV-2的mRNA疫苗。 n Engl J Med。 2020; 383（20）：1920-1931。 DOI：10.1056 / Nejmoa2022483 PubMed Google Scholar CrossRef</p><p> 3. Dan  JM﻿, Mateus  J﻿, Kato  Y﻿,   et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. ﻿   Science. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063 PubMed Google Scholar</p><p> 3.丹 JM，Mateus. j，kato y， 等等。免疫记忆对SARS-COV-2感染后最多8个月评估。科学。 2021; 371（6529）：EABF4063。 DOI：10.1126 / science.abf4063 PubMed Google学者</p><p> 4. Widge  AT﻿, Rouphael  NG﻿, Jackson  LA﻿,   et al; mRNA-1273 Study Group.  Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. ﻿   N Engl J Med. 2021;384(1):80-82. doi: 10.1056/NEJMc2032195 PubMed Google Scholar Crossref</p><p> 4. Widge. 在，鲁弗勒 NG，杰克逊 洛杉矶， 等等; mRNA-1273研究组。 SARS-COV-2 mRNA-1273疫苗接种后的反应耐久性。 n Engl J Med。 2021; 384（1）：80-82。 DOI：10.1056 / Nejmc2032195 PubMed Google Scholar Crossref</p><p> 5. Liu  Y﻿, Liu  J﻿, Xia  H﻿,   et al.  Neutralizing activity of BNT162b2-elicited serum: preliminary report. ﻿   N Engl J Med. Published online February 17, 2021. doi: 10.1056/NEJMc2102017 PubMed Google Scholar</p><p> 5.刘 刘 j，xia H， 等等。中和BNT162B2引发血清的活性：初步报告。 n Engl J Med。在线发布于20021年2月17日。Doi：10.1056 / Nejmc2102017 PubMed Google学者</p><p> 6. Vanderheiden  A﻿, Edara  VV﻿, Floyd  K﻿,   et al.  Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. ﻿   Curr Protoc Immunol. 2020;131(1):e116. doi: 10.1002/cpim.116 PubMed Google Scholar</p><p> 6. Vanderheiden. a，edara VV，Floyd k， 等等。用于测量SARS-COV-2中和抗体的快速聚焦减少中和试验测定的研制。 Curr protoc免疫素。 2020; 131（1）：E116。 DOI：10.1002 / CPIM.116 PUBMED Google Scholar </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://jamanetwork.com/journals/jama/fullarticle/2777898">https://jamanetwork.com/journals/jama/fullarticle/2777898</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/covid/">#covid</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/effective/">#effective</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/md/">#md</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>